Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLRB NASDAQ:HYFT NASDAQ:INKT NASDAQ:PDSB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLRBCellectar Biosciences$3.10-6.1%$2.92$2.43▼$20.60$13.15M0.43705,836 shs264,279 shsHYFTMindWalk$1.25+4.5%$1.19$0.44▼$3.25$57.75M0.65416,171 shs81,924 shsINKTMiNK Therapeutics$11.29+0.8%$11.00$6.34▼$76.00$56.20M0.47217,016 shs1,468 shsPDSBPDS Biotechnology$1.21+5.7%$0.84$0.51▼$1.92$65.28M1.51746,660 shs280,181 shs10 Best Stocks to Own in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Spring 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLRBCellectar Biosciences-6.52%+26.92%+20.00%+8.55%-54.95%HYFTMindWalk-5.51%+0.84%+9.09%-23.57%+119,999,900.00%INKTMiNK Therapeutics-0.18%-8.28%-3.53%+2.01%+60.91%PDSBPDS Biotechnology+7.55%+17.16%+24.18%+59.44%-1.72%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLRBCellectar Biosciences$3.10-6.1%$2.92$2.43▼$20.60$13.15M0.43705,836 shs264,279 shsHYFTMindWalk$1.25+4.5%$1.19$0.44▼$3.25$57.75M0.65416,171 shs81,924 shsINKTMiNK Therapeutics$11.29+0.8%$11.00$6.34▼$76.00$56.20M0.47217,016 shs1,468 shsPDSBPDS Biotechnology$1.21+5.7%$0.84$0.51▼$1.92$65.28M1.51746,660 shs280,181 shs10 Best Stocks to Own in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Spring 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLRBCellectar Biosciences-6.52%+26.92%+20.00%+8.55%-54.95%HYFTMindWalk-5.51%+0.84%+9.09%-23.57%+119,999,900.00%INKTMiNK Therapeutics-0.18%-8.28%-3.53%+2.01%+60.91%PDSBPDS Biotechnology+7.55%+17.16%+24.18%+59.44%-1.72%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLRBCellectar Biosciences 2.33Hold$11.00233.33% UpsideHYFTMindWalk 2.60Moderate Buy$5.00316.67% UpsideINKTMiNK Therapeutics 2.40Hold$35.00212.78% UpsidePDSBPDS Biotechnology 2.33Hold$9.00689.47% UpsideCurrent Analyst Ratings BreakdownLatest CLRB, INKT, PDSB, and HYFT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/5/2026CLRBCellectar Biosciences Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$11.004/24/2026INKTMiNK Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/21/2026PDSBPDS Biotechnology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/20/2026CLRBCellectar Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/16/2026HYFTMindWalk JonesTradingSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$5.004/15/2026HYFTMindWalk JonesTradingSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy4/15/2026PDSBPDS Biotechnology HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$15.004/1/2026INKTMiNK Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$35.003/13/2026HYFTMindWalk HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy3/13/2026HYFTMindWalk UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy3/10/2026CLRBCellectar Biosciences Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLRBCellectar BiosciencesN/AN/AN/AN/A$1.89 per shareN/AHYFTMindWalk$17.59M3.15N/AN/A$0.37 per share3.24INKTMiNK TherapeuticsN/AN/AN/AN/A($3.03) per shareN/APDSBPDS BiotechnologyN/AN/AN/AN/A$0.18 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLRBCellectar Biosciences-$21.79M-$9.53N/AN/AN/AN/A-298.05%-144.59%5/12/2026 (Estimated)HYFTMindWalk-$21.69M-$0.20N/AN/AN/A-66.79%-69.37%-39.74%N/AINKTMiNK Therapeutics-$12.49M-$2.97N/AN/AN/AN/AN/A-139.00%5/13/2026 (Estimated)PDSBPDS Biotechnology-$34.50M-$0.75N/AN/AN/AN/A-241.95%-90.36%5/13/2026 (Estimated)Latest CLRB, INKT, PDSB, and HYFT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2026Q1 2026INKTMiNK Therapeutics-$0.77N/AN/AN/AN/AN/A5/13/2026Q1 2026PDSBPDS Biotechnology-$0.15N/AN/AN/AN/AN/A5/12/2026Q1 2026CLRBCellectar Biosciences-$1.8850N/AN/AN/A$8.00 millionN/A3/31/2026Q4 2025INKTMiNK Therapeutics-$0.68-$0.54+$0.14-$0.54N/AN/A3/30/2026Q4 2025PDSBPDS Biotechnology-$0.20-$0.14+$0.06-$0.14N/AN/A3/12/2026Q3 2026HYFTMindWalk-$0.04-$0.06-$0.02-$0.06$3.50 million$3.00 million3/4/2026Q4 2025CLRBCellectar Biosciences-$1.19-$0.53+$0.66-$0.53N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCLRBCellectar BiosciencesN/AN/AN/AN/AN/AHYFTMindWalkN/AN/AN/AN/AN/AINKTMiNK TherapeuticsN/AN/AN/AN/AN/APDSBPDS BiotechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLRBCellectar BiosciencesN/A2.962.96HYFTMindWalk0.213.743.64INKTMiNK TherapeuticsN/A1.061.06PDSBPDS Biotechnology1.272.982.98Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLRBCellectar Biosciences16.41%HYFTMindWalk6.70%INKTMiNK Therapeutics2.87%PDSBPDS Biotechnology26.84%Insider OwnershipCompanyInsider OwnershipCLRBCellectar Biosciences5.04%HYFTMindWalk6.83%INKTMiNK Therapeutics22.48%PDSBPDS Biotechnology9.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLRBCellectar Biosciences104.24 million4.03 millionNo DataHYFTMindWalk8046.16 million43.00 millionN/AINKTMiNK Therapeutics304.98 million3.86 millionNo DataPDSBPDS Biotechnology2054.40 million49.40 millionOptionableCLRB, INKT, PDSB, and HYFT HeadlinesRecent News About These CompaniesPDS Biotech Announces Conference Call and Webcast for 2026 First Quarter Financial ResultsMay 6 at 8:00 AM | globenewswire.comPDS Biotechnology (PDSB) Projected to Post Quarterly Earnings on WednesdayMay 6 at 7:51 AM | marketbeat.comPDS Biotechnology Corporation (NASDAQ:PDSB) Short Interest Down 16.3% in AprilMay 1, 2026 | marketbeat.comPDS Biotechnology (NASDAQ:PDSB) and Immunome (NASDAQ:IMNM) Head-To-Head ContrastMay 1, 2026 | americanbankingnews.comPDS Biotechnology Corp.April 22, 2026 | barrons.comB. Riley Securities Sticks to Their Buy Rating for PDS Biotechnology (PDSB)April 17, 2026 | theglobeandmail.comPDSB stock hits 37-week high — here’s the latest on its therapy to treat metastatic colorectal cancerApril 15, 2026 | msn.comPDS Biotechnology (NASDAQ:PDSB) Earns Buy Rating from HC WainwrightApril 15, 2026 | marketbeat.comPDS Biotechnology Announces Promising Phase 2 Trial Results of PDS01ADC for Treatment of Colorectal Liver MetastasesApril 15, 2026 | quiverquant.comQPDS Biotech Announces Publication of Positive PDS01ADC Interim Phase 2 Clinical Trial Data from Stage 1 of NCI-led Metastatic Colorectal Cancer (mCRC) TrialApril 15, 2026 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: PDS Biotechnology (PDSB), Eli Lilly & Co (LLY) and Praxis Precision Medicines (PRAX)April 7, 2026 | theglobeandmail.comPDS Biotechnology Corporation (NASDAQ:PDSB) Q4 2025 earnings call transcriptApril 1, 2026 | msn.comPDS Biotechnology Corp (PDSB) Q4 2025 Earnings Call Highlights: Financial Discipline Amid ...March 31, 2026 | finance.yahoo.comPDS Biotechnology Corporation (PDSB) Q4 2025 Earnings Call TranscriptMarch 30, 2026 | seekingalpha.comPDS Biotechnology: Q4 Earnings SnapshotMarch 30, 2026 | finance.yahoo.comPDS Biotech Reports Full Year 2025 Financial Results and Provides Update on PDS0101 Phase 3 Program and PDS01ADC Clinical AdvancementMarch 30, 2026 | globenewswire.comPDS Biotech Announces Conference Call and Webcast for 2025 Fourth Quarter and Year End Financial ResultsMarch 24, 2026 | globenewswire.comPDS Biotech Announces Adoption of Amended Protocol for Phase 3 VERSATILE-003 Trial Incorporating Progression Free Survival (PFS) as Primary Endpoint for Interim Analysis and ...February 20, 2026 | uk.finance.yahoo.comPDS Biotech Announces Adoption of Amended Protocol for Phase 3 VERSATILE-003 Trial Incorporating Progression Free Survival (PFS) as Primary Endpoint for Interim Analysis and Potential Accelerated ApprovalFebruary 20, 2026 | globenewswire.comPDS Biotech Announces Presentation of Preliminary Results from Phase 2 Study of IL-12 Tumor Targeted Immunocytokine (PDS01ADC) in 3rd Line Metastatic Castration Resistant ...January 29, 2026 | markets.businessinsider.comPDS Biotechnology Corporation Reports 9.6 Months Median Progression-Free Survival from NCI-Led Study of PDS01ADC in Advanced Prostate CancerJanuary 28, 2026 | quiverquant.comQNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCLRB, INKT, PDSB, and HYFT Company DescriptionsCellectar Biosciences NASDAQ:CLRB$3.10 -0.20 (-6.06%) As of 11:22 AM Eastern This is a fair market value price provided by Massive. Learn more.Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.MindWalk NASDAQ:HYFT$1.25 +0.05 (+4.50%) As of 11:22 AM Eastern This is a fair market value price provided by Massive. Learn more.ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation. The company has research collaboration agreements with Pierre Fabre S.A for antibody discovery; and Elektrofi, Inc. to explore a high-concentration formulation of COVID-19 antibody cocktail, PolyTope TATX-03. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada.MiNK Therapeutics NASDAQ:INKT$11.28 +0.10 (+0.85%) As of 11:22 AM Eastern This is a fair market value price provided by Massive. Learn more.MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.PDS Biotechnology NASDAQ:PDSB$1.20 +0.07 (+5.70%) As of 11:22 AM Eastern This is a fair market value price provided by Massive. Learn more.PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein (TARP) for treating prostate and breast cancers; and PDS0103 for ovarian, colorectal, lung, and breast cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment; and PDS0104, a novel investigational Tyrosinase-related Protein 2 targeted immunotherapy that stimulates a potent targeted T cell attack against melanoma. Further, the company provides PDS0202, a novel investigational influenza vaccine that generates broad and robust antibody and T cell responses that provide protection against continually evolving strains of seasonal flu and potentially emerging pandemic flu. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. The company was founded in 2005 and is based in Princeton, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Wells Fargo’s Comeback Is Real—But Not Risk-Free IonQ Just Posted a Breakout Quarter—But 1 Problem Remains SLB’s Tough Quarter Masks a Powerful Long-Term Shift Super Micro Surges Over 20% as Margins Soar, Sales Fall Short Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
